These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 9308561

  • 1. Rediscovering mycophenolic acid: a review of its mechanism, side effects, and potential uses.
    Kitchin JE, Pomeranz MK, Pak G, Washenik K, Shupack JL.
    J Am Acad Dermatol; 1997 Sep; 37(3 Pt 1):445-9. PubMed ID: 9308561
    [Abstract] [Full Text] [Related]

  • 2. [Mycophenolate mofetil: a new immunosuppressive drug in dermatology and its possible uses].
    Geilen CC, Orfanos-Boeckel H, Offermann G, Orfanos CE.
    Hautarzt; 2000 Feb; 51(2):63-9. PubMed ID: 10743574
    [Abstract] [Full Text] [Related]

  • 3. Mycophenolate mofetil.
    Zwerner J, Fiorentino D.
    Dermatol Ther; 2007 Feb; 20(4):229-38. PubMed ID: 17970888
    [Abstract] [Full Text] [Related]

  • 4. Mycophenolic acid in dermatology a century after its discovery.
    Strathie Page SJ, Tait CP.
    Australas J Dermatol; 2015 Feb; 56(1):77-83. PubMed ID: 25557632
    [Abstract] [Full Text] [Related]

  • 5. Mycophenolate mofetil in pediatric renal transplantation.
    Weber LT, Höcker B, Mehls O, Tönshoff B.
    Minerva Urol Nefrol; 2003 Mar; 55(1):91-9. PubMed ID: 12773970
    [Abstract] [Full Text] [Related]

  • 6. Mycophenolate mofetil: a dermatologic perspective.
    Mydlarski PR.
    Skin Therapy Lett; 2005 Apr; 10(3):1-6. PubMed ID: 15986076
    [Abstract] [Full Text] [Related]

  • 7. Treatment of chronic plaque-stage psoriasis and psoriatic arthritis with mycophenolate mofetil.
    Grundmann-Kollmann M, Mooser G, Schraeder P, Zollner T, Kaskel P, Ochsendorf F, Boehncke WH, Kerscher M, Kaufmann R, Peter RU.
    J Am Acad Dermatol; 2000 May; 42(5 Pt 1):835-7. PubMed ID: 10775866
    [Abstract] [Full Text] [Related]

  • 8. Mycophenolate mofetil and skin diseases.
    Hartmann M, Enk A.
    Lupus; 2005 May; 14 Suppl 1():s58-63. PubMed ID: 15803935
    [Abstract] [Full Text] [Related]

  • 9. Mycophenolate mofetil as a systemic antipsoriatic agent: positive experience in 11 patients.
    Geilen CC, Arnold M, Orfanos CE.
    Br J Dermatol; 2001 Mar; 144(3):583-6. PubMed ID: 11260019
    [Abstract] [Full Text] [Related]

  • 10. Psoriasis vulgaris treated successfully with mycophenolate mofetil.
    Haufs MG, Beissert S, Grabbe S, Schütte B, Luger TA.
    Br J Dermatol; 1998 Jan; 138(1):179-81. PubMed ID: 9536244
    [Abstract] [Full Text] [Related]

  • 11. Mycophenolate mofetil in dermatology.
    Orvis AK, Wesson SK, Breza TS, Church AA, Mitchell CL, Watkins SW.
    J Am Acad Dermatol; 2009 Feb; 60(2):183-99; quiz 200-2. PubMed ID: 19150270
    [Abstract] [Full Text] [Related]

  • 12. Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update.
    Staatz CE, Tett SE.
    Arch Toxicol; 2014 Jul; 88(7):1351-89. PubMed ID: 24792322
    [Abstract] [Full Text] [Related]

  • 13. Mycophenolate mofetil in autoimmune and inflammatory skin disorders.
    Nousari HC, Sragovich A, Kimyai-Asadi A, Orlinsky D, Anhalt GJ.
    J Am Acad Dermatol; 1999 Feb; 40(2 Pt 1):265-8. PubMed ID: 10025760
    [Abstract] [Full Text] [Related]

  • 14. Plasma trough levels of mycophenolic acid do not correlate with efficacy and safety of mycophenolate mofetil in psoriasis.
    Daudén E, Sánchez-Peinado C, Ruiz-Genao D, García-F-Villalta M, Onate MJ, García-Díez A.
    Br J Dermatol; 2004 Jan; 150(1):132-5. PubMed ID: 14746627
    [Abstract] [Full Text] [Related]

  • 15. [Use of mycophenolate mofetil in kidney transplantation].
    Hrvacevic R, Ignjatovic Lj, Vavic N.
    Vojnosanit Pregl; 2001 Jan; 58(4):415-9. PubMed ID: 11712223
    [Abstract] [Full Text] [Related]

  • 16. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF).
    Allison AC, Eugui EM.
    Clin Transplant; 1996 Feb; 10(1 Pt 2):77-84. PubMed ID: 8680053
    [Abstract] [Full Text] [Related]

  • 17. Superior efficacy of enteric-coated mycophenolate vs mycophenolate mofetil in de novo transplant recipients: pooled analysis.
    Salvadori M, Bertoni E, Budde K, Holzer H, Civati G, Lien B, Arns W.
    Transplant Proc; 2010 May; 42(4):1325-8. PubMed ID: 20534293
    [Abstract] [Full Text] [Related]

  • 18. Mycophenolate mofetil: An update.
    Villarroel MC, Hidalgo M, Jimeno A.
    Drugs Today (Barc); 2009 Jul; 45(7):521-32. PubMed ID: 19834629
    [Abstract] [Full Text] [Related]

  • 19. Long-term safety of mycophenolate mofetil and cyclosporine: a review.
    Buell C, Koo J.
    J Drugs Dermatol; 2008 Aug; 7(8):741-8. PubMed ID: 18720690
    [Abstract] [Full Text] [Related]

  • 20. Enteric-coated mycophenolate sodium: safe conversion from mycophenolate mofetil in maintenance renal transplant recipients.
    Budde K, Glander P, Diekmann F, Dragun D, Waiser J, Fritsche L, Neumayer HH.
    Transplant Proc; 2004 Mar; 36(2 Suppl):524S-527S. PubMed ID: 15041401
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.